KEYMED BIOSCIENCES -0001 Total Liabilities
KEYMED BIOSCIENCES -0001 total liabilities. Based on the latest financial reports, KEYMED BIOSCIENCES -0001 (64Z) has total liabilities worth €1.44 Billion EUR (≈ $1.69 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 64Z asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of KEYMED BIOSCIENCES -0001 (2021–2025)
Total liabilities of KEYMED BIOSCIENCES -0001 from 2021 to 2025. This chart illustrates how KEYMED BIOSCIENCES -0001's total liabilities have evolved over time, based on quarterly financial data.
KEYMED BIOSCIENCES -0001 Competitors by Total Liabilities
The table below lists competitors of KEYMED BIOSCIENCES -0001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sai MicroElectronics Inc
SHE:300456
|
China | CN¥1.87 Billion |
|
Hyundai Steel
KO:004020
|
Korea | ₩15.40 Trillion |
|
Warby Parker Inc
NYSE:WRBY
|
USA | $380.33 Million |
|
Catena AB
ST:CATE
|
Sweden | Skr30.85 Billion |
|
Bilfinger SE
XETRA:GBF
|
Germany | €2.31 Billion |
|
Peabody Energy Corp
NYSE:BTU
|
USA | $2.17 Billion |
|
Ruentex Development Co Ltd
TW:9945
|
Taiwan | NT$86.41 Billion |
|
Colt CZ Group SE
PR:COLT
|
Czech Republic | Kč48.41 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down KEYMED BIOSCIENCES -0001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 64Z asset base.
Liquidity & Leverage Metrics
KEYMED BIOSCIENCES -0001 Total Liabilities Ratios Explained
KEYMED BIOSCIENCES -0001 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how KEYMED BIOSCIENCES -0001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for KEYMED BIOSCIENCES -0001 (2021–2025)
The table below shows the annual total liabilities of KEYMED BIOSCIENCES -0001 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.44 Billion ≈ $1.69 Billion |
+11.71% |
| 2024-12-31 | €1.29 Billion ≈ $1.51 Billion |
+44.11% |
| 2023-12-31 | €896.11 Million ≈ $1.05 Billion |
+51.09% |
| 2022-12-31 | €593.10 Million ≈ $693.39 Million |
+105.17% |
| 2021-12-31 | €289.07 Million ≈ $337.96 Million |
-- |
About KEYMED BIOSCIENCES -0001
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis;… Read more